Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 19/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5054550 | 1.00 | CXCR4 (0.48) | CXCR4CYP2D6CHRM2ADRA2ADRD2 | |
| SCHEMBL3263194 | 1.00 | CXCR4 (0.48) | CXCR4CYP2D6CHRM2ADRA2ADRD2 | |
| SCHEMBL30096632 | 1.00 | CXCR4 (0.48) | CXCR4CYP2D6CHRM2ADRA2ADRD2 | |
| Bromide SCHEMBL18628756 | 0.99 | CXCR4 (0.47) | CXCR4CYP2D6CHRM2ADRA2ADRD2 | |
| Hydrochloric Acid SCHEMBL18628724 | 0.99 | CXCR4 (0.47) | CXCR4CYP2D6CHRM2ADRA2ADRD2 | |
| SCHEMBL4760298 | 0.92 | CXCR4 (0.47) | CXCR4 | |
| SCHEMBL4760832 | 0.86 | CXCR4 (0.44) | CXCR4CYP2D6CHRM2ADRA2ADRD2 | |
| Levacetylleucine SCHEMBL30331228 | 0.81 | ALDH1A1 (0.44) | CXCR4 | |
| SCHEMBL30096692 | 0.78 | CXCR4 (0.44) | CXCR4CYP2D6CHRM2ADRA2ADRD2 | |
| SCHEMBL2083508 | 0.77 | CXCR4 (0.37) | CXCR4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465889-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2017-03-22 | — | — | EP | claimed |
| US-7354932-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2008-04-08 | — | — | US | disclosed |
| US-20040019058-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019058-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | CXCR4 2/4885CYP2D6 3057/4885CHRM2 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.